Congratulations to Zhang Ziang’s PhD graduation
On May 26th, 2023, Dr. Zhang Ziang successfully defended their doctoral dissertation. During the Ph. D training under the supervising of Prof. Quan Jummin and Prof. Li Qinkai, he has done great jobs in their own research fields.
To overcome the limitation of the clinical application of uricases, Dr. Zhang Ziang used genetic engineering to develop anti-inflammatory long-acting recombinant uricase IL-1Ra-GA3-AgUox by sequential fusing IL-1Ra and albumin-binding domain (GA3) to the N-terminal end of Arthrobacter globiformis uricase (AgUox). IL-1Ra-GA3-AgUox provides a foundation to develop effective and safe uricases as urate lowering therapy in the treatment of hyperuricemia and gout.